Welcome to the first episode of Breast Cancer Breakthroughs, where we’ll share the latest research discoveries with the breast cancer community. The largest breast cancer conference of the year, the 2022 San Antonio Breast Cancer Symposium, took place in December 2022. During the conference, we learned that women can safely pause hormone therapy to have children and that antibody drug conjugates are poised to revolutionize breast cancer treatment for new groups of patients. We break down these findings and more with two Komen-affiliated experts who presented at the symposium, Advocate in Science Thelma Brown and Komen Scholar Dr. Sara Tolaney.
Check out our resources:
•POSITIVE Trial: ascopost.com/news/december-2022/patients-with-breast-cancer-who-interrupted-endocrine-therapy-to-pursue-pregnancy-did-not-experience-worse-short-term-recurrence-rates/
•Having children after breast cancer www.komen.org/breast-cancer/survivorship/health-concerns/having-children/
•Antibody drug conjugates: www.komen.org/breast-cancer/treatment/emerging-areas/drug-therapies/
•Information on Enhertu (Trastuzumab Deruxtecan): www.komen.org/breast-cancer/facts-statistics/research-studies/topics/trastuzumab-deruxtecan-enhertu-treatment-for-metastatic-breast-cancer/
•Information on Trodelvy (Sacituzumab Govitecan): www.komen.org/breast-cancer/facts-statistics/research-studies/topics/sacituzumab-govitecan-trodelvy-treatment-for-metastatic-breast-cancer/
•Clinical Trials Information Page: clinicaltrials.komen.org/
Time Stamps:
00:00 Introduction
01:32 POSITIVE Trial
06:11 Antibody Drug Conjugates
11:25 Clinical Trial Barriers
17:01 Take-aways from SABCS